Clinical Trial Update: Extension Study of Participants From SPG302-ALZ-101 [Phase 2]

View source ↗

Summary

The extension study of SPG302-ALZ-101 in Alzheimer's disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• SPG302

Snippet

Sponsor: Spinogenix | Conditions: Alzheimer's Disease | Phase 2 | Status: TERMINATED